Javascript must be enabled to continue!
STUDY OF PREDICTIVE VALUE OF RAD51 EXPRESSION FOR THE EFFECTIVENESS OF PLATINUM-BASED THERAPY OF HIGH-GRADE SEROUS OVARIAN CARCINOMA
View through CrossRef
Background. The search for novel markers of predictive significance is an important issue in the management of ovarian cancer (OC) patients. Recently, the expression of the RAD51 protein, involved in homologous DNA repair has been shown to be predictive of platinum chemotherapy response in OC patients. Aim. To establish the relationship between the level of RAD51 protein expression in patients with high-grade serous ovarian carcinoma (SOC) after neoadjuvant platinum chemotherapy and the frequency of recurrence, disease progression, and relapse-free survival. Materials and Methods. RAD51 status was assessed in the archival histological material of 30 patients with SOC of stage III who received perioperative platinum-based chemotherapy. RAD51 expression was analyzed using a double-staining technique in samples containing at least 100 geminin-positive tumor cells. RAD51 status was considered positive if > 10% of geminin-positive nuclei were positive for RAD51. Results. In 16 of 30 cases, the tumor had a RAD51–positive status (homologous repair proficient, HRP), and in 14 — RAD51-negative (homologous repair deficient, HRD). We found that the risk of disease progression in patients with RAD51 HRP status was 3.42 times higher compared to patients with RAD51 HRD status (HR = 3.42; 95% CI 1.38—8.46; p = 0.008). In SOC patients with RAD51 HRP status, a significantly higher (p < 0.001) rate of disease progression over 3 to 12 months of postoperative observation compared to patients with RAD51 HRD status was detected. Conclusions. RAD51 expression is predictive for the response of highgrade SOC to platinum therapy.
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Title: STUDY OF PREDICTIVE VALUE OF RAD51 EXPRESSION FOR THE EFFECTIVENESS OF PLATINUM-BASED THERAPY OF HIGH-GRADE SEROUS OVARIAN CARCINOMA
Description:
Background.
The search for novel markers of predictive significance is an important issue in the management of ovarian cancer (OC) patients.
Recently, the expression of the RAD51 protein, involved in homologous DNA repair has been shown to be predictive of platinum chemotherapy response in OC patients.
Aim.
To establish the relationship between the level of RAD51 protein expression in patients with high-grade serous ovarian carcinoma (SOC) after neoadjuvant platinum chemotherapy and the frequency of recurrence, disease progression, and relapse-free survival.
Materials and Methods.
RAD51 status was assessed in the archival histological material of 30 patients with SOC of stage III who received perioperative platinum-based chemotherapy.
RAD51 expression was analyzed using a double-staining technique in samples containing at least 100 geminin-positive tumor cells.
RAD51 status was considered positive if > 10% of geminin-positive nuclei were positive for RAD51.
Results.
In 16 of 30 cases, the tumor had a RAD51–positive status (homologous repair proficient, HRP), and in 14 — RAD51-negative (homologous repair deficient, HRD).
We found that the risk of disease progression in patients with RAD51 HRP status was 3.
42 times higher compared to patients with RAD51 HRD status (HR = 3.
42; 95% CI 1.
38—8.
46; p = 0.
008).
In SOC patients with RAD51 HRP status, a significantly higher (p < 0.
001) rate of disease progression over 3 to 12 months of postoperative observation compared to patients with RAD51 HRD status was detected.
Conclusions.
RAD51 expression is predictive for the response of highgrade SOC to platinum therapy.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Targeting the DNA damage repair protein RAD51 alters fibroblast metabolism and enhances apoptosis in pulmonary fibrosis
Targeting the DNA damage repair protein RAD51 alters fibroblast metabolism and enhances apoptosis in pulmonary fibrosis
Summary
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by aberrantly acti...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Abstract
Background
2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct enti...
RAD51AP1 is a versatile RAD51 modulator
RAD51AP1 is a versatile RAD51 modulator
Summary
RAD51AP1 is an emergent key factor in homologous recombination (HR), the major pathway for accurate repair of DNA double-strand breaks, a...
Abstract 875: PAX8 protein detection in serum of patients with serous ovarian cancer
Abstract 875: PAX8 protein detection in serum of patients with serous ovarian cancer
Abstract
Introduction: The paired-box (PAX) genes encode a family of transcription factors (TFs) with critical roles in the formation of tissues and organs during em...

